(MedPage Today) — CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma.
In 2021, the FDA approved idecabtagene vicleucel (ide-cel, Abecma) for patients…
Source link : https://www.medpagetoday.com/spotlight/asco-mm/116214
Author :
Publish date : 2025-06-24 14:47:00
Copyright for syndicated content belongs to the linked Source.
